|
1. BIOLOGIE
|
|
|
|
Brain Cancer Cells Hijack Gene “On Switches” to Drive Tumor Growth [NCI]
|
|
|
|
|
|
Many current cancer treatments target altered proteins produced by key oncogenes. But, in light of the new findings, “we are thinking about how we can target all this extra DNA that’s important on these circles,” Dr. Scacheri said. “We are thinking about how to exploit this new knowledge for therapies.”
|
|
|
|
|
|
|
|
2.13 ETIOLOGIE - NDMA
|
|
|
|
3.1 PRÉVENTION - TABAC
|
|
|
UK tobacco shares rise on U.S. e-cigarette ban exemptions [Reuters]
|
|
|
|
|
|
Brokerage Jefferies said that while vaping sales would take a near-term hit from the new rules, the overall financial impact for BAT and Imperial would be minimal as most users would either switch to menthol or tobacco, or even to higher-margin traditional tobacco products.
|
|
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
What if a Vaping Tax Encouraged Cigarette Smoking? [NY Times]
|
|
|
|
|
|
“By decreasing the extent to which people use e-cigarettes, you decrease quitting of conventional cigarettes,” said W. Kip Viscusi, a professor of law, economics and management at Vanderbilt University, who was not involved in the research but has studied tobacco policy extensively.
|
|
|
|
|
|
|
3.3 PRÉVENTION - VACCINS
|
|
|
|
Even a Single Dose of HPV Vaccine May Provide Protection [NY Times]
|
|
|
|
|
|
The lead author, Ashish A. Deshmukh, an assistant professor at the UTHealth School of Public Health in Houston, said that while these results are encouraging, three doses remain best for now. “Until we have clinical trials,” he said, “we should not rely on one dose.”
|
|
|
|
|
|
|
3.4.1 CHIMIOPRÉVENTION - ASPIRINE
|
|
|
|
4.15 DÉP., DIAG. & PRONO. - IMAGERIE
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.4 IMMUNOTHÉRAPIES - ESSAIS
|
|
|
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
|
5.2 PHARMA
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic [Xconomy]
|
|
|
|
|
|
Black Diamond is developing drugs to treat cancers with defined genetic mutations. The company has developed proprietary technology, dubbed Mutation Allostery Pharmacology (MAP), to analyze population-level genetic sequencing data in order to find mutations that drive cancer growth, according to the filing.
|
|
|
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
6.4 MÉDICO-ÉCO
|
|
|
|
6.6 PUBLICATIONS
|
|
|
Who Is Competing to Own Researcher Identity? [The Scholarly Kitchen]
|
|
|
|
|
|
We are witnessing the transformation away from a journal-centric model of scholarly publishing towards a researcher-centric model of scholarly communication. Success in this new environment requires engagement with researcher identity, which is a struggle even for most of the largest publishing houses.
|
|
|
|
|
|
|
6.9 CONTROVERSES
|
|
|